Download PDF
Semin Thromb Hemost 2001; 27(5): 531-536
DOI: 10.1055/s-2001-17963
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Effect of Thrombin Inhibitors and a Glycoprotein IIb/IIIa Receptor Antagonist in an Ex Vivo Human Experimental Thrombosis Model

Kaweh Zokai, Lukas Piazolo, Job Harenberg
  • First Department of Medicine, University Hospital, Mannheim, Germany
Further Information

Publication History

Publication Date:
22 October 2001 (online)

    Permissions and Reprints

ABSTRACT

The development of new antithrombotic drugs to inhibit the blood coagulation system and to block receptors of platelets represents an important area of medical research. The results of the efficacy in animal models are of critical importance for the further development of these compounds for human use. The transferability of such data from animal to human species still remains controversial. The antithrombotic effects of direct thrombin inhibitors and a glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonist were investigated in an experimental thrombosis model using human blood in order to analyze the feasibility of such a model.

KEYWORD

Thrombosis model - GPIIb/IIIa antagonist - thrombin inhibitors - blood coagulation - platelets

REFERENCES

  • 1 Hara T, Yokoyama A, Morishima Y, Kunitada S. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.  Thromb Res . 1995;  80 99-104
    CrossrefPubMedGoogle Scholar
  • 2 Tapparelli C, Metternich R, Gfeller P, Gafner B, Powling M. Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin.  Thromb Haemost . 1995;  73 641-647
    PubMedGoogle Scholar
  • 3 Dickneite G, Seiffge D, Diehl K H. Pharmacological characterization of a new 4-amidinophenylalanine thrombin-inhibitor (CRC 220).  Thromb Res . 1995;  77 357-368
    CrossrefPubMedGoogle Scholar
  • 4 Shirakura S, Higo K, Takeda M, Karasawa A. Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs.  Jpn J Pharmacol . 1994;  65 93-98
    PubMedGoogle Scholar
  • 5 Coller B S. GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab.  Thromb Haemost . 1997;  78 730-735
    PubMedGoogle Scholar
  • 6 Ammar T, Scudder L E, Coller B S. In vitro effects of platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time.  Circulation . 1997;  95 614-617
    PubMedGoogle Scholar
  • 7 Reverter J C, Beguin S, Kessels H. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody.  J Clin Invest . 1996;  98 863-874
    CrossrefPubMedGoogle Scholar
  • 8 Aguejouf O, Imbault P, Jourdan A. Experimental models of arterial thrombosis.  Ann Cardiol Angeiol (Paris) . 1995;  44 109-118
    PubMedGoogle Scholar
  • 9 Chesebro J H, Fuster V. Thrombosis in unstable angina.  N Engl J Med . 1992;  327 192-194
    PubMedGoogle Scholar
  • 10 Chierchia S, Patrono C. Role of platelets and vascular eicosanoids in the pathophysiology of ischemic heart disease.  Fed Proc . 1987;  46 81(Abst)
    PubMedGoogle Scholar
  • 11 Ruggeri Z M. New insights into mechanism of platelet adhesion and aggregation.  Semin Hematol . 1994;  31 229-239
    PubMedGoogle Scholar
  • 12 Sixma J J. Interaction of blood platelets with the vessel wall. In: Bloom A, Forbes CD, ed. Haemostasis and Thrombosis, 3rd ed New York: Churchill Livingstone 1994: 259-285
    Google Scholar
  • 13 Jaffe E A. Cell biology of endothelial cells.  Hum Pathol . 1987;  18 234-239
    PubMedGoogle Scholar
  • 14 DeGroot P G, Sixma J J. Platelet adhesion.  Br J Haematol . 1990;  75 308-312
    PubMedGoogle Scholar
  • 15 Gray E, Tubbs J, Thomas S. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity.  Thromb Haemost . 1995;  73 675-679
    PubMedGoogle Scholar
  • 16 Orvim U, Barstad R M, Vlasuk G P, Sakariassen K S. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an in vitro model of shear-dependent human thrombogenesis.  Arterioscler Thromb Vasc Biol . 1995;  15 2188-2194
    PubMedGoogle Scholar
  • 17 Hirigoyen M B, Zhang W X, Weinberg H. A standardized model of microvenous thrombosis.  J Reconstr Microsurg . 1995;  11 455-459
    PubMedGoogle Scholar
  • 18 Delon-Martin C, Vogt C, Chignier E. Venous thrombosis generation by means of high-intensity focused ultrasound.  Ultrasound Med Biol . 1995;  21 113-119
    CrossrefPubMedGoogle Scholar
  • 19 Krupinski K, Ferber H, Breddin H K, Bielawiec M. The antithrombotic effect of thromboxane receptor antagonist HN 11500 on thrombus formation in laser thrombosis model and platelet function tests.  Acta Haematol Pol . 1994;  25 235-242
    PubMedGoogle Scholar
  • 20 Jourdan A, Aguejouf O, Imbault P, Doutremepuich F, Inamo J. Experimental thrombosis model induced by free radicals. Application to aspirin and other different substances.  Thromb Res . 1995;  79 109-123
    CrossrefPubMedGoogle Scholar
  • 21 Saniabadi A R, Umemura K, Matsumoto N, Sakuma S, Nakashima M. Vessel wall injury and arterial thrombosis induced by a photochemical reaction.  Thromb Haemost . 1995;  73 868-872
    PubMedGoogle Scholar
  • 22 The EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty.  N Engl J Med . 1994;  330 956-961
    CrossrefPubMedGoogle Scholar
  • 23 The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization.  N Engl J Med . 1997;  336 1689-1696
    CrossrefPubMedGoogle Scholar
  • 24 The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study.  Lancet . 1997;  349 1429-1435
    CrossrefPubMedGoogle Scholar
  • 25 The RAPPORT Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction.  Circulation . 1998;  98 734-741
    PubMedGoogle Scholar
  • 26 Harenberg J, Schuler M, Waibel S, Heptner W, Zimmermann R. Influence of low molecular weight heparin on fibrin formation and platelet aggregation.  Haemostasis . 1985;  15 29-30
    PubMedGoogle Scholar
  • 27 Harenberg J. Thrombin-antithrombin (TAT) complexes. In: Jespersen J, Bertina RM, Haverkate F, eds. ECAT Assay Procedures. Laboratory Techniques in Thrombosis. A Manual. 2nd ed. Boston: Kluwer Academic Publishers 1998: 209-216
    Google Scholar
  • 28 Files J C, Malpass T W, Yee E K, Ritchie J L, Harker L A. Studies of human platelet alpha-granule release in vivo.  Blood . 1981;  58 607-618
    PubMedGoogle Scholar
      >